News >

Wave of Therapies Being Developed in AL Amyloidosis Space

Gina Columbus
Published: Wednesday, Jan 24, 2018

Sandy W. Wong, MD

Sandy W. Wong, MD
Immunoglobulin light chain amyloidosis (AL amyloidosis), known as the most common form of systemic amyloidosis and associated with an underlying plasma cell dyscrasia, is frequently difficult to recognize because it presents similarly to a variety of other hematologic disorders.

on Hematologic Malignancies, Wong, an assistant clinical professor in the Division of Hematology/Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discussed some of these therapeutic advancements and recent data that have shown excitement in this landscape.

OncLive: What developments have we recently seen in this field?

Wong: The developments have basically been separated into 2 major categories. One is anti-plasma cell therapy and the other one is anti-amyloid fibril therapy. In terms of the anti-plasma therapies, the new development has been the publication of the phase I trial for ixazomib in AL amyloidosis. It looks to be quite an active drug with a relatively good safety profile.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication